| abstract |
The present technology relates to methods of detecting genetic mutations that cause intracranial tumors such as pituitary adenomas, meningiomas, and craniopharyngiomas. The methods disclosed herein are used to determine whether a patient bearing an intracranial tumor would benefit from or be predicted to respond to treatment with an individual therapeutic agent or a particular combination of therapeutic agents. Kits for practicing this method are also provided. |